









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on August 2024

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
RSV Vaccines				
3) New formulations & extensions to use				
Nil this month				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
4) Products considered by NICE				
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
Nil this month				
6) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines and pathways were presented to and approved at the August 2024 meeting of the APC:

- Prasugrel
- Ticagrelor 90mg
- Lipid guideline
- Managing migraine and cluster headaches (updated – pending commissioning of atogepant)
- Sublingual immunotherapy (pending approval at NY&Y APC)

The following Drug information leaflets were presented to and approved at the August 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the August 2024 meeting of the APC:

- Amiodarone SCF

Other documents presented to and approved at the August 2024 meeting of the APC:

- Request for reclassification of sublingual licensed immunotherapy (pending approval at NY&Y APC).